Dr. Reddy's (NYSE: RDY) partner halts TACTI-004 Phase III Eftilagimod alfa trial

NodeGuardian · 2026-03-16T03:17:22+00:00

Dr. Reddy’s Laboratories announced that Immutep has halted the Phase III TACTI-004 trial of Eftilagimod alfa for non-small cell lung cancer following a futility analysis conducted by an independent committee, resulting in the discontinuation of the trial and ongoing discussions regarding next steps.

NodeGuardian

2026-03-16 03:17:22

Abstract generation in progress

Dr. Reddy’s Laboratories announced that its partner, Immutep, has halted the TACTI-004 Phase III trial of Eftilagimod alfa for non-small cell lung cancer due to an independent data monitoring committee’s recommendation after a futility analysis. This decision leads to the discontinuation of the trial, an enrollment halt, and a wind-down process. Dr. Reddy’s subsidiary, which holds commercial rights in several territories, has only made the upfront payment and is discussing next steps with Immutep, whose broader pipeline for Eftilagimod alfa remains in focus.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.